Alzheimer’s Disease Therapeutics and Diagnostics Industry
Description
Wiseguyreports.Com Adds “Alzheimer’s Disease Therapeutics and Diagnostics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database
Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer’s disease. One in nine people aged 65 and above has Alzheimer’s disease. By 2050, the number of people aged 65 and above affected with Alzheimer’s disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer’s therapeutics and diagnostics worldwide.
Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.
The global Alzheimer’s Disease Therapeutics and Diagnostics market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Alzheimer’s Disease Therapeutics and Diagnostics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Alzheimer’s Disease Therapeutics and Diagnostics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
Access Sample Report @ https://www.wiseguyreports.com/sample-request/3871191-global-alzheimer-s-disease-therapeutics-and-diagnostics-market
The following manufacturers are covered:
Namenda
Aricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Lundbeck
Daiichi Sankyo
Novartis
TauRx
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Biomarkers
Cholinesterase inhibitors
NMDA receptor antagonists
Brain imaging
Blood tests
Segment by Application
Drugs Market
Diagnostics Market
Leave a Query @ https://www.wiseguyreports.com/enquiry/3871191-global-alzheimer-s-disease-therapeutics-and-diagnostics-market
Table of Contents (Some Major Key players & points)
7 Company Profiles and Key Figures in Alzheimer’s Disease Therapeutics and Diagnostics Business
7.1 Namenda
7.1.1 Namenda Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served
7.1.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification
7.1.3 Namenda Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019)
7.1.4 Main Business and Markets Served
7.2 Aricept
7.3 Exelon
7.4 Solanezumab
7.5 Gantenerumab
7.6 Verubecestat
7.7 Pfizer
7.8 Eisai
7.9 Actavis
7.10 Lundbeck
7.11 Daiichi Sankyo
7.12 Novartis
7.13 TauRx
Continued…
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)